Skip to content

US · NUTX · MEDICAL - CARE FACILITIES

Nutex Health, Inc. (NUTX) intrinsic value and stock valuation

$162.64as of 2026-11-21 · Mkt cap 1.08B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Nutex Health, Inc. DCF and intrinsic value

InvestorsCraft values NUTX with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from NUTX’s statements →

Nutex Health, Inc. Graham Number

Graham Number: $129.10d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Care Facilities Houston, TX 77056 nutexhealth.com

How the business is doing

Fiscal 2009–2025, USD

Revenue
$875.3M+26.1% 5y CAGRd
20092025
Net income
$70.8M-7.8% 5y CAGRd
20092025
Free cash flow
$245.6M+57.3% 5y CAGRd
20102025
Total equity
$423.4M+23.5% 5y CAGRd
20102025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2009–2025, USD
20252024202320222021
Revenue$875.3M$480M$247.7M$219.3M$331.5M
Operating income$275.6M$130.6M-$-31.77M-$-406.6M$170.3M
Net income$70.8M$52.2M-$-45.79M-$-424.78M$132.6M
EPSd$10.5M$10.2M-$-10.38M-$-100.42M$33.6M
Operating cash flow$248.1M$23.2M$1.26M$50.6M$173.4M
Capital expenditure-$-2.53M-$-2.3M-$-9.5M-$-14.63M-$-36.93M
Free cash flow$245.6M$20.9M-$-8.24M$36M$136.5M
Total assets$918.5M$655.3M$398.3M$431.8M$394.7M
Total debt$351.4M$340.3M$275.8M$267.2M$178.6M
Net debt$165.8M$296.7M$253.8M$233M$142.4M
Total equity$423.4M$201.9M$79.1M$120.3M$191.6M
Cash and short-term investments$185.6M$43.6M$22M$34.3M$36.1M
Income statement
20252024202320222021
Revenue$875.3M$480M$247.7M$219.3M$331.5M
Cost of revenue$431M$283.7M$212.9M$203.9M$152.3M
Gross profit$444.3M$196.3M$34.8M$15.4M$179.3M
Research and development expenses$0.00$0.00$0.00$0.00$290K
Selling, general and administrative expenses$168.7M$58.6M$36.1M$20M$5.46M
Other expenses$0.00$7.08M$30.5M$402M$3.27M
Operating expenses$168.7M$65.6M$66.6M$422M$9.02M
Cost and expenses$599.6M$349.3M$279.4M$625.9M$161.3M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$22.2M$19.9M$16.3M$12.5M$6.2M
Depreciation and amortization$20.5M$19M$17.6M$13.1M$7.76M
Ebitda$287.5M$148.7M-$-14.58M-$-394.03M$183.5M
Operating income$275.6M$130.6M-$-31.77M-$-406.6M$170.3M
Total other income/expenses, net-$-30.84M-$-20.87M-$-16.72M-$-13.05M-$-770K
Income before tax$244.8M$109.8M-$-48.49M-$-419.65M$169.5M
Income tax expense$64.4M$14.5M-$-5.07M$13.1M$970K
Net income$70.8M$52.2M-$-45.79M-$-424.78M$132.6M
Weighted average shares outstanding$6.36M$5.1M$4.41M$4.23M$4.02M
Weighted average diluted shares outstanding$6.76M$5.1M$4.41M$4.23M$3.95M
Balance sheet
20252024202320222021
Cash and short-term investments$185.6M$43.6M$22M$34.3M$36.1M
Net receivables$325.4M$236.1M$62.8M$58.3M$114.8M
Inventory$2.87M$2.85M$3.39M$3.53M$2.81M
Total current assets$538.8M$292.5M$90.9M$98M$154M
Property, plant and equipment, net$343.9M$324.7M$269.4M$295.2M$238.4M
Goodwill and intangible assets$35.2M$29.5M$37.6M$38.2M$1.82M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$379.7M$362.8M$307.4M$333.8M$240.6M
Total assets$918.5M$655.3M$398.3M$431.8M$394.7M
Accounts payable$49M$14M$25.3M$23.9M$17.7M
Short-term debt$23.3M$27.7M$20.1M$21.1M$13.2M
Deferred revenue$0.00$0.00$0.00$0.00$170K
Total current liabilities$157.9M$140.9M$58.3M$54.9M$37.7M
Long-term debt$328.1M$312.6M$255.7M$246.1M$165.4M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$337.2M$312.6M$260.8M$256.6M$165.4M
Capital lease obligations$308.1M$299.9M$235.3M$229M$89.5M
Total liabilities$495.1M$453.4M$319.1M$311.4M$203.1M
Common stock$10K$10K$680K$650K$590K
Retained earnings-$-286.19M-$-356.89M-$-409.07M-$-363.29M$102.3M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$423.4M$201.9M$79.1M$120.3M$191.6M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$351.4M$340.3M$275.8M$267.2M$178.6M
Net debt$165.8M$296.7M$253.8M$233M$142.4M
Cash flow statement
20252024202320222021
Net income$180.4M$95.3M-$-43.42M-$-432.74M$168.5M
Depreciation and amortization$20.5M$19M$17.6M$13.1M$7.66M
Stock-based compensation$117M$16.6M$2.84M$190K$0.00
Change in working capital-$-87.74M-$-104.4M-$-1.66M$64.3M$2.75M
Accounts receivable-$-89.32M-$-173.41M-$-4.58M$58.1M-$-6.62M
Inventory-$-20K$540K$140K-$-720K-$-1.09M
Accounts payable$37.9M-$-10.72M-$-2.25M$9.69M$6.27M
Net cash provided by operating activities$248.1M$23.2M$1.26M$50.6M$173.4M
Investments in property, plant and equipment-$-2.53M-$-2.3M-$-9.5M-$-14.63M-$-36.93M
Acquisitions, net$0.00-$-360K-$-1.74M$10.3M-$-50K
Net cash used for investing activities-$-5.24M-$-2.67M-$-11.24M-$-4.34M-$-36.98M
Common stock issued$0.00$9.2M$0.00$4.76M$0.00
Common stock repurchased-$-5M$0.00$0.00$0.00$0.00
Dividends paid-$-74.28M-$-6.44M-$-5.21M-$-51.23M-$-144.34M
Net cash used for financing activities-$-97.95M$1.09M-$-2.27M-$-48.13M-$-125.85M
Net change in cash$145.2M$21.6M-$-12.25M-$-1.86M$10.6M
Cash at end of period$185.9M$43.6M$22M$34.3M$36.1M
Operating cash flow$248.1M$23.2M$1.26M$50.6M$173.4M
Capital expenditure-$-2.53M-$-2.3M-$-9.5M-$-14.63M-$-36.93M
Free cash flow$245.6M$20.9M-$-8.24M$36M$136.5M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Nutex Health, Inc.

        Nutex Health, Inc. functions as a technology-powered enterprise delivering healthcare services, structured into two key segments: its Hospital division and its Population Health Management division. The Hospital division is tasked with developing and overseeing various healthcare models, encompassing micro-hospitals, specialized medical centers, and hospital outpatient facilities. This segment currently owns and operates 21 locations spanning eight different states. Meanwhile, the Population Health Management division establishes and manages provider networks, such as independent physician associations. Additionally, its management services organizations furnish administrative, operational, and support assistance to its associated hospitals and physician groups. A proprietary, cloud-based technology platform within this division is crucial; it aggregates patient and provider data from multiple information systems, settings, and sources to construct a holistic view, thereby enabling more effective care delivery. The company maintains its corporate headquarters in Houston, Texas.

        CEO
        Thomas T. Vo
        Employees
        944
        Beta
        1.97

        Explore

        Frequently asked questions

        What is the intrinsic value of Nutex Health, Inc. (NUTX)?

        Nutex Health, Inc. (NUTX) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is NUTX undervalued?

        NUTX trades at a price of $162.64 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.